ArticleOncoTargets and therapy2025
Icariin Inhibits Lung Adenocarcinoma Progression Through TP53-Mediated Ferroptosis.
Article in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lung adenocarcinoma (LUAD) represents the predominant histological subtype of non-small cell lung cancer (NSCLC) and is linked to a diminished overall survival (OS) rate. Icariin (ICA), the principal bioactive compound found in the medicinal plant Epimedium, has demonstrated significant efficacy in inhibiting tumor progression. Ferroptosis, an emerging mechanism of cellular demise, offers a promising avenue for therapeutic intervention in oncology. Nonetheless, the function and modulation of ferroptosis in LUAD are still significantly under-investigated. Methods: A potential ferroptosis target was identified via bioinformatics analysis. Levels of reactive oxygen species (ROS) and ferroptosis-associated markers were quantified, while MTT, wound healing (WH), and Transwell assays were conducted to assess the effect of ICA on the malignant behavior of the LUAD cell line A549. The antitumor activity of ICA was further validated in vivo. Additionally, transcriptome sequencing and bioinformatics analysis were performed to explore ICA-induced molecular regulatory changes associated with the malignant phenotype of tumors. Results: Bioinformatics analysis revealed that TP53 is a potential target of ferroptosis. Cellular experiments demonstrated that ICA induces ferroptosis in a dose-dependent manner, significantly reducing the proliferation, migration, and invasion abilities of A549 cells. Furthermore, the ferroptosis inhibitor Fer-1 can partially reverse both the ferroptosis and the increased expression of TP53 induced by ICA, indicating that ICA suppresses the malignant behavior of A549 cells by inducing TP53-mediated ferroptosis. This mechanism of action was further validated by in vivo experiments. Additional transcriptome sequencing and bioinformatics analysis showed that the mechanism by which ICA inhibits the proliferation of lung cancer cells may be related to its effects on cell cycle and metastasis-related gene sets, lipid metabolism, tumor immune microenvironment, and tumor-promoting pathways, including cholesterol metabolism, cortisol synthesis and secretion, and the PI3K-Akt signaling pathway. Conclusion: ICA demonstrates antitumor properties in LUAD via TP53-mediated ferroptosis, consequently suppressing cellular proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.